by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Bio Technology : July 2009
THE DIFFERENCE BETWEEN WHAT YOU’RE QUOTED AND CHARGED Now that’s a bitter pill to swallow Have you been told your drug development project would cost $100,000 and take 6 months but cost $1 million and took a year? Get it right the first time! Speak to us at Mayne Pharma International* about our contract development and manufacturing services. We have over 3 decades of experience developing and manufacturing complex products for oral drug delivery. We provide expertise in: Formulation development Oral formulations: • Capsules, • Tablets, • Solutions, emulsions, suspensions. The sector needs to restructure university incentives and focus on cutting-edge, readily commercialisable technologies. Companies should not be built around single products, which should help them raise adequate funding and make them more resilient. When needed, companies must make the tough decisions to terminate projects that do not show early commercial viability. Building a sustainable industry is not about avoiding shareholder dilution at all costs. It is about ensuring that the company and the technology are as well funded as possible to either reach commercialisation quickly or demonstrate sufficient value to attract a licensor. It is only through measures such as these that Australia will develop a truly successful and sustainable biotech industry that can provide consistent financial returns to patient shareholders. * The above is an excerpt from Ernst & Young’s Beyond Borders 2009: Global Biotechnology Report. Modified release oral formulations Sustained release - deliver steady levels of drug over 12 to 24 hours following a single dose. Pulsed release - deliver pulses of drug over 12 to 24 hours following a single dose. Modified release - immediate release of some drug and delayed release of the balance. Delayed release - target drug to a specific site particularly avoiding release in the stomach via enteric coating. Technical advice and proprietary technology to assist with oral formulation challenges including bioavailability, solubility and taste. Licensed to handle CII/S8 compounds and utilise chlorinated solvents and alcohols in the manufacturing process. Dermaceuticals: • Gels, • Creams and pastes, • Lotions. Manufacturing: • Clinical trial batches, • Pilot and commercial manufacturing scales, • FDA, TGA, MHRA, TPD approved site. Analytical methods development, transfer, testing and stability. Regulatory affairs support Flexible packaging options and worldwide distribution services. Mayne Pharma International* 1538 Main North Rd Salisbury South South Australia 5107, Australia Email: email@example.com Phone: +618 8209 2666 Fax: +618 8281 6998 *A wholly owned subsidiary of Hospira Inc., Lake Forest, Ill, USA. P08-1620/R1 mayne